OKYO - OKYO Pharma Ltd

QQQ $ 604.92 $ 3.94 (0.66 %)

DIA $ 461.73 $ 2.22 (0.48 %)

SPY $ 665.28 $ 3.75 (0.57 %)

TLT $ 91.09 $ -0.14 (-0.15 %)

GLD $ 391.28 $ -7.46 (-1.88 %)

Previous Close

$ 2.24

Open

$ 2.11

Bid

$ 2.02 x 2

Ask

$ 2.29 x 500

Day's Range

$ 2.09 - $ 2.25

52 Week Range

$ 0.90 - $ 3.35

Volume

201,755

Average Volume

Market Cap

84.25M

Beta (5Y Monthly)

$ 0.76

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

OKYO Pharma Says Executive Chairman Gabrie...
10/16/2025 12:33:46

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat ...

HC Wainwright & Co. Reiterates Buy on OKYO...
09/23/2025 10:42:24

HC Wainwright & Co. analyst Yi Chen reiterates OKYO Pharma (NASDAQ:OKYO) with a Buy and maintains $7 price target.

OKYO Pharma Announces Plans For Next Stage...
09/22/2025 12:37:17

OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat n...

12 Health Care Stocks Moving In Thursday's...
07/17/2025 12:08:10

12 Health Care Stocks Moving In Wednesday'...
07/16/2025 21:06:00

OKYO Pharma Plans To Meet With FDA Followi...
07/16/2025 13:26:35

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neurop...

OKYO Pharma Announces Top-Line Data From R...
07/16/2025 13:22:56

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neurop...

12 Health Care Stocks Moving In Tuesday's ...
07/15/2025 12:07:58

12 Health Care Stocks Moving In Monday's I...
06/16/2025 17:06:02

Okyo Pharma Announced That Its CEO, Gary S...
05/19/2025 11:03:48

HC Wainwright & Co. Reiterates Buy on OKYO...
05/05/2025 11:14:22

HC Wainwright & Co. analyst Yi Chen reiterates OKYO Pharma (NASDAQ:OKYO) with a Buy and maintains $7 price target.

FDA Grants OKYO Pharma Fast Track Designat...
05/01/2025 11:12:03

OKYO Pharma Plans To Accelerate Clinical D...
04/30/2025 11:04:31

Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP") patients was initiated in October 2024 and designed a...

OKYO Pharma Announces Data In Long-Term St...
03/31/2025 12:18:07

Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term StabilityUrcosimod stable in single-us...

OKYO Pharma Files For Fast Track Designati...
03/10/2025 12:32:30

HC Wainwright & Co. Reiterates Buy on OKYO...
02/18/2025 12:08:20

HC Wainwright & Co. analyst Yi Chen reiterates OKYO Pharma (NASDAQ:OKYO) with a Buy and maintains $7 price target.

HC Wainwright & Co. Reiterates Buy on OKYO...
02/14/2025 18:01:35

HC Wainwright & Co. analyst Yi Chen reiterates OKYO Pharma (NASDAQ:OKYO) with a Buy and maintains $7 price target.

OKYO Pharma Says Its Lead Asset, OK-101, H...
02/12/2025 12:11:50

HC Wainwright & Co. Reiterates Buy on OKYO...
02/10/2025 16:52:39

HC Wainwright & Co. analyst Yi Chen reiterates OKYO Pharma (NASDAQ:OKYO) with a Buy and maintains $7 price target.

OKYO Pharma Announced Today That It Has Be...
01/31/2025 12:15:10